Eubiologics Surges as COVID-19 Treatment & Vaccine Development Stocks Rebound
Seoul, South Korea – November 13, 2025 – Shares of Eubiologics (206650) jumped 6.93% today, leading a broader rally in the COVID-19 treatment adn vaccine development sector. The thematic index rose 3.02% reversing recent adjustments and signaling renewed investor interest.
Eubiologics, a biological products and pharmaceuticals research and development company, is benefitting from the upswing. The surge follows a period of sector volatility, with institutional investors driving the current rebound through KRW 79.953 billion in net purchases. Foreign investors contributed KRW 52.643 billion in net purchases, while individual investors recorded net sales of KRW 137.047 billion.
Other notable performers within the theme included Aptabio, up 10.43%, and Peptron, rising 8.33%, followed by Nature Cell with a 7.05% increase.
Quantitative financial analysis further highlights Eubiologics’ potential. The company ranks 3rd out of 29 stocks within the theme, exceeding the average scores for growth potential, stability, and profitability. This ranking is based on a robo-algorithm analysis of sales growth rate, equity capital growth rate, debt ratio, current ratio, ROA, and ROE.
